Nordic Nanovector ASA (OSE:NANO) is pleased to announce that it will
host a Capital Markets Day on Tuesday 31 May 2016 in Oslo. The program
will begin at 08:30 CEST, followed by lunch. A formal invitation,
including the full programme and registration details, will be
distributed at a later stage.
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARCs) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018. Betalutin®
comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low
intensity radionuclide (lutetium-177). The preliminary data has shown
promising efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with the
first regulatory submission anticipated in 1H 2019. Nordic Nanovector
intends to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company
is committed to developing its pipeline of ARCs to treat multiple
selected cancer indications. Further information about the Company can
be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section
5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160419006929/en/
Copyright Business Wire 2016